- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05650866
Sicherheit und Verträglichkeit eines neuartigen implantierbaren Geräts zur Behandlung von erektiler Dysfunktion
Sicherheit und Verträglichkeit eines neuartigen implantierbaren Geräts zur Behandlung der erektilen Dysfunktion nach radikaler Prostatektomie
The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.
The main questions it aims to answer are:
- Is the device safe?
- Does the device works well? Are the participants satisfied with the device?
Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:
- Come to the hospital for follow-up visits,
- Complete questionnaires,
- Activate the device every day,
- Measure erection hardness.
Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Victoria
-
Fitzroy, Victoria, Australien, 3065
- St. Vincent's Private Hospital
-
Melbourne, Victoria, Australien, 3050
- Royal Melbourne Hospital
-
North Melbourne, Victoria, Australien, 3051
- Australian Prostate Centre
-
Richmond, Victoria, Australien, 3121
- Epworth HealthCare
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men of ages between 30-70 years;
- Men with indication for nerve-sparing prostatectomy surgery;
- Localised prostate cancer considered suitable for bilateral nerve sparing prostatectomy according to clinical criteria
- International Index of Erectile Function (IIEF-15) erectile function domain score equal to or greater than 26 prior prostatectomy;
- Men interested in minimizing the effect of radical prostatectomy on erectile function;
- Ability to read and understand patient information materials and willingness to sign a written informed consent.
Exclusion Criteria:
- Men with neurological disease, including a history of spinal cord injury or trauma;
- IIEF-15 erectile function domain score less than 26 prior prostatectomy;
- Failure to demonstrate adequate nocturnal erectile function prior prostatectomy;
- History of erectile dysfunction, priapism and Peyronie disease;
- History of previous pelvic surgery, trauma or irradiation therapy;
- Currently have an active implantable device;
- Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions;
- Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation;
- Inability to understand and demonstrate device use instructions;
- Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications;
- Patient unwillingness to engage in sexual activity;
- Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function;
- Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months;
- Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study;
- Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Implanted group
The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday. |
The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function. |
|
Kein Eingriff: Control group
Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Occurrence of adverse events
Zeitfenster: 6 months
|
Adverse events will be reported using MedDRA terminology. |
6 months
|
|
Occurrence of surgical complications
Zeitfenster: 6 months
|
Surgical complications will be ranked according to the Clavien-Dindo classification |
6 months
|
|
Occurrence of device deficiencies
Zeitfenster: 6 months
|
Device deficiencies will be systematically reported and recorded. |
6 months
|
|
Pain
Zeitfenster: 6 months
|
Patients will be asked to rate pain on a visual analog scale (from 0 to 10) |
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Device effectiveness
Zeitfenster: 6 months
|
Erectile response obtained when activating the study device will be objectively assessed by measuring penile rigidity with the RigiScan device. |
6 months
|
|
Subjective Device effectiveness
Zeitfenster: 6 months
|
Erectile function will be subjectively assessed by asking participants to complete validated questionnaires (International Index of Erectile Function, IIEF-15 and Erection Hardness Score, EHS). |
6 months
|
|
Erectile function recovery
Zeitfenster: 6 months
|
Nocturnal penile erections will be assessed with the RigiScan device. Nocturnal erections reflect the extent of recovery of natural erectile function. |
6 months
|
|
Delineation of the surgical implantation procedure
Zeitfenster: 6 months
|
The surgeon will record information related to the implantation (duration, position of the device, grading ease of implantation steps, and any comments). |
6 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- CP-1.5400
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .